What do systematic reviews say?

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic antibiotics alone vs systematic antibiotics plus antibiotic lock solution

It is very uncertain whether systemic antibiotics alone changes cure: successful eradication of the infection compared with systematic antibiotics plus antibiotic lock solution (very low certainty).

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  RR 1.61 [1.16, 2.23]
  1 study · 64 participants
  Very low

Systemic antibiotics alone vs systematic antibiotics plus antibiotic lock solution

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention may leads to higher registration behaviour: ICC adjusted (dichotomous) (low certainty).

• Interventions for increasing solid organ donor registration 2021 · Cochrane Headline outcomes only
  RR 1.3 [1.19, 1.43]
  16 studies · 1294065 participants
  Low

Intervention not reported

The intervention may leads to higher registration intention (dichotomous) (low certainty).

• Interventions for increasing solid organ donor registration 2021 · Cochrane Headline outcomes only
  RR 1.21 [1.03, 1.42]
  10 studies · 10838 participants
  Low

Intervention not reported

• Interventions for increasing solid organ donor registration 2021 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 3572 participants
  Low

Heparin vs placebo

• Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Heparin vs placebo

Heparin showed no clear difference in major bleeding events: unfractionated heparin compared with placebo (low certainty).

• Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
  RR 2.92 [0.89, 9.56]
  3 studies · 155 participants
  Low

Heparin vs placebo

Heparin showed no clear difference in major bleeding events: all heparin compared with placebo (low certainty).

• Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
  RR 2.7 [0.89, 8.19]
  3 studies · 180 participants
  Low

Heparin vs placebo

It is very uncertain whether heparin changes readmissions to intensive care: all heparin compared with placebo (very low certainty).

• Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
  RR 0.68 [0.12, 3.9]
  3 studies · 180 participants
  Very low

Heparin vs placebo

• Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Heparin vs placebo

• Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Heparin vs placebo

• Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Eculizumab vs placebo or alternative treatment

• Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  100 participants
  Very low

Ravulizumab vs placebo or alternative treatment

• Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  56 participants
  Very low

Ravulizumab vs placebo or alternative treatment

• Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  56 participants
  Very low

Ravulizumab vs placebo or alternative treatment

• Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  44 participants
  Very low

Ravulizumab vs placebo or alternative treatment

• Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  58 participants
  Very low

Ravulizumab vs placebo or alternative treatment

• Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  58 participants
  Very low

Eculizumab vs placebo or alternative treatment

• Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  100 participants
  Very low